Heartland Advisors Inc. Increases Stake in DENTSPLY SIRONA Inc. $XRAY

Heartland Advisors Inc. lifted its position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 490.6% in the 1st quarter, Holdings Channel.com reports. The fund owned 953,250 shares of the medical instruments supplier’s stock after acquiring an additional 791,850 shares during the period. Heartland Advisors Inc.’s holdings in DENTSPLY SIRONA were worth $11,058,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in DENTSPLY SIRONA during the 1st quarter valued at about $26,000. Eurizon Capital SGR S.p.A. bought a new stake in DENTSPLY SIRONA in the fourth quarter worth about $26,000. Caitong International Asset Management Co. Ltd lifted its stake in DENTSPLY SIRONA by 337.9% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 2,122 shares during the last quarter. Farther Finance Advisors LLC boosted its position in shares of DENTSPLY SIRONA by 119.1% during the fourth quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock valued at $43,000 after buying an additional 2,051 shares during the period. Finally, Performa Ltd US LLC boosted its position in shares of DENTSPLY SIRONA by 116.1% during the fourth quarter. Performa Ltd US LLC now owns 4,250 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 2,283 shares during the period. 95.70% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at DENTSPLY SIRONA

In other news, Director Michael J. Barber purchased 15,175 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were purchased at an average price of $9.88 per share, for a total transaction of $149,929.00. Following the completion of the purchase, the director owned 55,943 shares in the company, valued at approximately $552,716.84. This represents a 37.22% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Brian P. Mckeon acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The stock was purchased at an average price of $10.12 per share, with a total value of $101,200.00. Following the completion of the acquisition, the director directly owned 10,000 shares of the company’s stock, valued at $101,200. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 35,160 shares of company stock valued at $351,179 in the last ninety days. Corporate insiders own 0.46% of the company’s stock.

DENTSPLY SIRONA Stock Performance

Shares of NASDAQ:XRAY opened at $14.06 on Friday. The firm’s 50 day simple moving average is $10.81 and its 200-day simple moving average is $11.74. The company has a debt-to-equity ratio of 1.52, a quick ratio of 0.98 and a current ratio of 1.53. DENTSPLY SIRONA Inc. has a one year low of $9.40 and a one year high of $17.09. The firm has a market cap of $2.82 billion, a PE ratio of -4.46, a price-to-earnings-growth ratio of 1.67 and a beta of 0.89.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The firm had revenue of $880.00 million during the quarter, compared to analysts’ expectations of $841.80 million. During the same quarter in the previous year, the firm posted $0.43 EPS. The firm’s revenue for the quarter was up .1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities analysts predict that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current year.

Wall Street Analyst Weigh In

XRAY has been the topic of several recent analyst reports. Weiss Ratings downgraded DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Citigroup started coverage on DENTSPLY SIRONA in a report on Wednesday, April 15th. They set a “sell” rating and a $10.00 price objective for the company. Mizuho cut their price objective on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. UBS Group reduced their target price on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Finally, BMO Capital Markets initiated coverage on DENTSPLY SIRONA in a research report on Wednesday, July 8th. They set a “market perform” rating and a $12.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $13.42.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.